WDHD1 and cancer: Considering the success of the combined use of atezolizumab plus paclitaxel in metastatic TNBC, the combination of paclitaxel and immunotherapy in patients with high WDHD1 expression holds promise for enhancing the efficacy of cancer treatment [139].